Olulanu Aina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Olulanu Aina has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Anna-Liisa Hänninen
Glykos Finland Oy, Helsinki, Finland. 1
43 shared publications - Annamari Heiskanen
Glykos Finland Oy, Helsinki, Finland. 1
43 shared publications - Brian Geist
Janssen Pharmaceuticals, Spring House, Pennsylvania
43 shared publications - Donna M. Klein
Janssen Pharmaceuticals, Spring House, Pennsylvania
43 shared publications - Henna Pynnönen
Glykos Finland Oy, Helsinki, Finland. 1
43 shared publications - Jacqueline Kinyamu-Akunda
24Oncology Discovery Department, Johnson & Johnson, Spring House, Pennsylvania
43 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Digestion of lintuzumab-mcvc-MMAE DAR4 (lintuzumab vedotin) by cynomolgus monkey liver microsomes at pH 4.5.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Digestion of lintuzumab-mcvc-MMAE DAR4 (lintuzumab vedotin) by cynomolgus monkey liver microsomes at pH 4.5.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Individual and mean serum T-MMAU toxicokinetic parameters following three i.v. bolus doses of T-mavg-MMAU DAR4 in male cynomolgus monkeys.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Individual and mean serum T-MMAU toxicokinetic parameters following three i.v. bolus doses of T-mavg-MMAU DAR4 in male cynomolgus monkeys.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Mean plasma MMAE toxicokinetic estimates following weekly i.v. doses of free MMAE to Sprague-Dawley rats.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Mean plasma MMAE toxicokinetic estimates following weekly i.v. doses of free MMAE to Sprague-Dawley rats.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Lysosomal degradation of T-mavg-MMAU DAR8.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Lysosomal degradation of T-mavg-MMAU DAR8.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Effect of cysteine protease inhibitor E-64 on lysosomal degradation of T-mavg-MMAU DAR8.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Effect of cysteine protease inhibitor E-64 on lysosomal degradation of T-mavg-MMAU DAR8.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Digestion of lintuzumab-mavg-MMAU DAR8 by cynomolgus monkey liver microsomes at pH 4.5.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Digestion of lintuzumab-mavg-MMAU DAR8 by cynomolgus monkey liver microsomes at pH 4.5.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Characterization of T-mavg-MMAU DAR8.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Characterization of T-mavg-MMAU DAR8.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Lysosomal degradation of non-hydrolyzed Cys-mavg-MMAU linker-payload molecule.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Lysosomal degradation of non-hydrolyzed Cys-mavg-MMAU linker-payload molecule.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Individual and mean serum MMAU toxicokinetic parameters following three i.v. bolus doses of T-mavg-MMAU DAR4 in male cynomolgus monkeys.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Individual and mean serum MMAU toxicokinetic parameters following three i.v. bolus doses of T-mavg-MMAU DAR4 in male cynomolgus monkeys.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Characterization of DAR4 ADCs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Characterization of DAR4 ADCs.